P076: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct‐acting antiviral treatments

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|S2|58-58

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.S2, 2015-06, pp. : 58-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply to direct‐acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4269-4270

John Wiley & Sons Inc

Access to resources Recommend Favorite

Direct‐acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4268-4269

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 373-381

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 7-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 20, Iss. 1, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite